DOP2016000308A - Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer - Google Patents
Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncerInfo
- Publication number
- DOP2016000308A DOP2016000308A DO2016000308A DO2016000308A DOP2016000308A DO P2016000308 A DOP2016000308 A DO P2016000308A DO 2016000308 A DO2016000308 A DO 2016000308A DO 2016000308 A DO2016000308 A DO 2016000308A DO P2016000308 A DOP2016000308 A DO P2016000308A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- salts
- cancer
- tiadiazol
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 7
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 abstract 2
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación se refiere a los compuestos de la Fórmula (I): (I) y a las sales de ellos adecuadas para usos farmacéuticos, donde Q, R, R1 y R2 poseen cualesquiera de los significados que se definen en la presente memoria descriptiva. La divulgación también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir las enfermedades mediadas por GLS1, incluyendo el cáncer. La divulgación asimismo se refiere a las formas cristalinas de los compuestos de la Fórmula (I) y sales de ellos adecuadas para usos farmacéuticos; a composiciones farmacéuticas que comprenden dichos compuestos y sales; a kits que comprenden dichos compuestos y sales; a métodos de preparación de dichos compuestos y sales; y a métodos para tratar las enfermedades mediadas por la quinasa GLS1, incluido el cáncer, utilizando dichos compuestos y sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409624.2A GB201409624D0 (en) | 2014-05-30 | 2014-05-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000308A true DOP2016000308A (es) | 2017-03-15 |
Family
ID=51214473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000308A DOP2016000308A (es) | 2014-05-30 | 2016-11-23 | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer |
Country Status (40)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) * | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201731511A (zh) * | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
| US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| CN110741003B (zh) * | 2017-06-13 | 2021-07-23 | 南京明德新药研发有限公司 | 作为gls1抑制剂的化合物 |
| JP2019064976A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| ES2939506T3 (es) | 2018-10-16 | 2023-04-24 | Medshine Discovery Inc | Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer |
| ES3010507T3 (en) * | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| KR20260022308A (ko) * | 2023-05-10 | 2026-02-19 | 리얼 테라퓨틱스, 인크. | 글루타미나제의 소분자 억제제 |
| CN116854582B (zh) * | 2023-07-10 | 2025-08-29 | 泰州葛林美克医药科技有限公司 | 一种对映纯α-甲氧基苯乙酸的制备方法 |
| CN117003745B (zh) * | 2023-07-20 | 2024-06-07 | 南京市第一医院 | Gls1/hdac双靶点抑制剂及其合成方法和应用 |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288956A1 (en) * | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2012170664A2 (en) | 2011-06-10 | 2012-12-13 | President And Fellows Of Harvard College | Methods of cancer treatment and prevention through the modulation of sirt4 activity |
| CN108785305B (zh) * | 2011-11-21 | 2021-10-29 | 卡利泰拉生物科技公司 | 谷氨酰胺酶的杂环抑制剂 |
| EP2895623B1 (en) * | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| HUE056078T2 (hu) | 2012-11-16 | 2022-01-28 | Calithera Biosciences Inc | Heterociklusos glutamináz inhibitorok |
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| HK1220640A1 (zh) | 2012-12-03 | 2017-05-12 | Calithera Biosciences, Inc. | 用谷氨醯胺酶的杂环抑制剂治疗癌症 |
-
2014
- 2014-05-30 GB GBGB1409624.2A patent/GB201409624D0/en not_active Ceased
-
2015
- 2015-05-27 CR CR20160558A patent/CR20160558A/es unknown
- 2015-05-27 CN CN201580041233.9A patent/CN106795150B/zh active Active
- 2015-05-27 RS RS20181101A patent/RS57876B1/sr unknown
- 2015-05-27 AU AU2015265703A patent/AU2015265703B2/en active Active
- 2015-05-27 SM SM20180516T patent/SMT201800516T1/it unknown
- 2015-05-27 DK DK15726266.8T patent/DK3148994T3/en active
- 2015-05-27 TN TN2016000511A patent/TN2016000511A1/en unknown
- 2015-05-27 LT LTEP15726266.8T patent/LT3148994T/lt unknown
- 2015-05-27 NZ NZ726790A patent/NZ726790A/en not_active IP Right Cessation
- 2015-05-27 EP EP15726266.8A patent/EP3148994B1/en active Active
- 2015-05-27 SI SI201530403T patent/SI3148994T1/sl unknown
- 2015-05-27 PE PE2016002393A patent/PE20170148A1/es unknown
- 2015-05-27 BR BR112016028002-4A patent/BR112016028002B1/pt active IP Right Grant
- 2015-05-27 AP AP2016009578A patent/AP2016009578A0/en unknown
- 2015-05-27 CA CA2949598A patent/CA2949598C/en active Active
- 2015-05-27 PL PL15726266T patent/PL3148994T3/pl unknown
- 2015-05-27 JP JP2017514983A patent/JP6538830B2/ja active Active
- 2015-05-27 ES ES15726266.8T patent/ES2688396T3/es active Active
- 2015-05-27 WO PCT/GB2015/051537 patent/WO2015181539A1/en not_active Ceased
- 2015-05-27 US US15/314,562 patent/US10040788B2/en active Active
- 2015-05-27 MY MYPI2016704405A patent/MY192861A/en unknown
- 2015-05-27 HR HRP20181490TT patent/HRP20181490T1/hr unknown
- 2015-05-27 SG SG11201609880QA patent/SG11201609880QA/en unknown
- 2015-05-27 PT PT15726266T patent/PT3148994T/pt unknown
- 2015-05-27 HU HUE15726266A patent/HUE039879T2/hu unknown
- 2015-05-27 EA EA201692260A patent/EA030937B1/ru not_active IP Right Cessation
- 2015-05-27 MX MX2016015738A patent/MX2016015738A/es unknown
- 2015-05-27 KR KR1020167036577A patent/KR20170005875A/ko not_active Abandoned
- 2015-05-28 UY UY0001036145A patent/UY36145A/es not_active Application Discontinuation
- 2015-05-29 TW TW104117531A patent/TWI693220B/zh not_active IP Right Cessation
- 2015-05-29 AR ARP150101720A patent/AR100694A1/es unknown
-
2016
- 2016-11-17 IL IL249020A patent/IL249020B/en active IP Right Grant
- 2016-11-23 DO DO2016000308A patent/DOP2016000308A/es unknown
- 2016-11-28 GT GT201600250A patent/GT201600250A/es unknown
- 2016-11-29 CL CL2016003074A patent/CL2016003074A1/es unknown
- 2016-11-30 NI NI201600176A patent/NI201600176A/es unknown
- 2016-11-30 SV SV2016005330A patent/SV2016005330A/es unknown
- 2016-12-01 PH PH12016502394A patent/PH12016502394A1/en unknown
-
2018
- 2018-07-02 US US16/025,455 patent/US10294221B2/en active Active
- 2018-09-20 CY CY181100975T patent/CY1120836T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CR20160558A (es) | Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| CO2017001523A2 (es) | Novedosas pirimidinas 2,5-sustituidas | |
| CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| AR101389A1 (es) | Composición que contiene apomorfina y un catión de metal divalente |